Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2015

Jun 24, 2015

33651_dirs_2015-06-23_4a6b46bd-3ebf-4931-b49b-c4791a6eb354.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2015-06-19

Reporting Person: Hillsberg Sanford (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-06-19 Stock Option (right to buy) $1.77 A 100000 Acquired 2025-06-19 Common Stock (100000) Direct

Footnotes

F1: The Issuer's Board of Directors approved the stock option grant on April 17, 2015, subject to stockholder approval of an amendment to the Amended and Restated 2007 Incentive Plan of the Issuer (the "Plan") to increase the number of shares of common stock available under the Plan. The Issuer's stockholders approved such amendment on June 19, 2015.

F2: The stock option vests in four equal quarterly installments over a period of one year beginning three months after June 19, 2015.